Hypotension Pipeline Review, H2 2018 - Identify and Track Emerging Players in the Market and their Portfolios - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Hypotension - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Hypotension - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hypotension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypotension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypotension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and IND/CTA Filed stages are 1, 1, 1, 2 and 1 respectively.
Hypotension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
2. Report Coverage
3. Hypotension - Overview
4. Hypotension - Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Products under Development by Companies
8. Hypotension - Therapeutics Assessment
9. Assessment by Target
10. Assessment by Mechanism of Action
11. Assessment by Route of Administration
12. Assessment by Molecule Type
13. Hypotension - Companies Involved in Therapeutics DevelopmentBCO Pharma Ltd Cerecor Inc La Jolla Pharmaceutical Company Theravance Biopharma Inc TrioxBio Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/2kdnzf/hypotension?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180925006089/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/25/2018 03:01 PM/DISC: 09/25/2018 03:01 PM